RAC1 and neoplasm: A new meta‐analysis of 14 different studies with a total of 1793 cancer patients found that high levels of Rac1 in different cancer types including prostate, breast, hepatocellular, and non‐small‐cell lung cancer were linked to tumour malignancy, indicating that Rac1 overexpression may be a potential biomarker for cancer progression 25.